Group 1 - Aidi Kang Holdings has signed a full acquisition of Suzhou Yuande Youqin Medical Laboratory Co., Ltd. and Suzhou Yuande Weikang Biomedicine Co., Ltd., marking a strategic move in the precision diagnosis of blood diseases [1] - The acquisition aims to strengthen Aidi Kang's technical barriers and market leadership in the high-end specialty testing field [1][4] - The signing ceremony was attended by key officials and executives, indicating the significance of this acquisition within the industry [1] Group 2 - Yuande Youqin has rapidly developed since its establishment in 2017, creating a comprehensive MICM precision diagnosis platform for hematological tumors, covering various blood system diseases [3] - The laboratory has received multiple authoritative certifications, demonstrating its strong management capabilities and compliance with international standards [3] - Yuande Youqin provides over 200,000 testing services annually, serving more than 400 tertiary hospitals with over 300 testing items [3] Group 3 - Yuande Weikang, established in 2014, specializes in flow cytometry detection and has developed various testing kits for blood diseases, with multiple GMP-standard workshops [3] - The company focuses on providing professional and standardized blood disease detection solutions, enhancing its research and development capabilities [3] Group 4 - Aidi Kang aims to integrate high-quality resources through this acquisition to expand service capabilities and deepen professional advantages [4] - The acquisition of Yuande Youqin will enhance Aidi Kang's expertise in high-value ICL projects, while the acquisition of Yuande Weikang will extend its capabilities in diagnostic reagent research and production [4] - This strategic integration is expected to improve Aidi Kang's innovation and operational efficiency, further solidifying its leading position in the industry [4]
艾迪康控股(09860)全资收购元德友勤、元德维康，血液病诊断商业版图再扩张